A New Chapter for Arbutus Biopharma: FDA Lifts Long-Standing Hold on Hepatitis B Drug

What a difference a day, or in this case, a regulatory decision, can make! After a rather prolonged and, one can only imagine, somewhat agonizing wait, the U.S. Food and Drug Administration (FDA) has finally given Arbutus Biopharma Corporation (NASDAQ:ABUS) the green light. On October 22, 2026, the FDA officially lifted the clinical hold on Arbutus's Investigational New Drug (IND) application for AB-101, a crucial step forward for their hepatitis B treatment. This isn't just any bureaucratic update; it ends a three-year-plus freeze that began way back in April 2023, undoubtedly a moment of immense relief and renewed hope for the company and, importantly, for patients.

So, what exactly is AB-101, and why is this news so significant? Well, it's an oral PD-L1 inhibitor, which sounds a bit technical, but essentially, it's designed to awaken and empower a patient's own immune system to specifically target and fight off the hepatitis B virus (HBV). Think of it as a way to help the body help itself, which is a really promising avenue in drug development, especially for chronic conditions like HBV where effective treatments are always in high demand.

Before the hold, Arbutus had already been diligently working on AB-101, conducting a Phase 1a/1b clinical trial, known as AB-101-001. This initial study looked at things like safety, how well patients tolerated the drug, and how it behaved in the body, both in healthy individuals and those living with chronic HBV. And the results? Quite encouraging, actually. The data suggested AB-101 was generally well-tolerated, which is always a crucial first hurdle. What's more, it demonstrated high receptor occupancy in seven chronic HBV patients and, quite notably, a detectable dip in hepatitis B surface antigen in two of those patients at a 30mg dose. While it's early days, these are the kinds of signals researchers get excited about.

Now, for a bit of a financial subplot that’s also shaping Arbutus's trajectory. Just recently, in August, the company unveiled plans for a substantial stock repurchase, aiming to buy back up to $230 million of its common stock. They're doing this through what's called a modified Dutch auction tender offer, with a price range set between $5 and $5.75 per share. It's a significant move, certainly, signaling confidence from within the company itself. But where's all this cash coming from, you might wonder?

Well, CEO Lindsay Androski shed some light on that, explaining that this impressive buyback is directly connected to a settlement reached with Moderna Inc. (NASDAQ:MRNA) back in March 2026. The initial payment from that agreement landed in Arbutus's coffers in July, totaling a rather hefty sum of approximately $178 million. This figure even includes reimbursements for litigation costs, which, let's be honest, can really add up. So, it seems Arbutus is not only getting back on track with its drug development but also bolstering its financial standing, which is a fantastic position to be in.

With the FDA's clinical hold finally lifted and a solid financial foundation reinforced by the Moderna settlement, Arbutus Biopharma appears poised for an exciting new chapter. This renewed ability to advance AB-101 in the U.S. could very well mark a pivotal moment for the company, potentially bringing a much-needed new treatment option closer to patients battling chronic Hepatitis B. It’s certainly a development worth watching, wouldn't you say?